

S. VANDEWOESTYNE<sup>1</sup>, A. CANTAGREL<sup>2</sup>, P. CESTAC<sup>1</sup>, M.C. MORIN<sup>1</sup>, V. CALMELS<sup>1</sup>, E. CIVADE<sup>1</sup>.  
<sup>1</sup>CHU DE TOULOUSE, Pharmacy, Toulouse, France — <sup>2</sup>CHU DE TOULOUSE, Unit of rheumatology, Toulouse, France.

## BACKGROUND

Biotherapies are mostly used in the treatment of chronic inflammatory rheumatism, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Because they expose patients to a higher risk of infection, a urinary dipstick test (UDT) is performed in all patients who receive biotherapies.

## PURPOSE

The aim of this study was to evaluate the relevance of systematically performing a UDT in patients in the rheumatology day hospitalisation unit.

## MATERIALS AND METHODS

A UDT was done for each patient during hospitalization. When they were positive (positive nitrites and/or leukocytes strong), a cytobacteriological examination of urine (CBEU) was performed as well as a summary of clinical information.

## RESULTS

553 UDT were performed in 354 patients over 2 months. Median age of the patients was 56 years and 66% were female.

From the 553 UDT performed, only 15 (3%) were positive:

- 10 UDT had only strong leukocytes
- 5 had only positive nitrites.


3 positive UDT did not lead to a CBEU:

- 2 of them did not show any clinical signs and biotherapies were injected.
- The third patient was already septic on arrival and was receiving antibiotics.

Of the 12 CBEU performed, 6 showed significant bacteriuria:

- 5 positive for *Escherichia coli*
- 1 for *Enterococcus faecalis*.

Among these 6 patients, all females : 3 had asymptomatic bacteriuria and received their biotherapy and 3 were symptomatic. 2 patients were diagnosed with cystitis and pyelonephritis was discovered in a third patient. All were treated with an appropriate dose of ofloxacin. Only the patient with pyelonephritis did not receive biotherapy; for the other 2, the injection was delayed.



## CONCLUSION:

Given the low frequency of abnormalities in the UDT, the therapeutic approach was modified in 3 cases and each time patients showed clinical signs. According to the literature, the risk of infection is higher during the first 6 months of treatment with biotherapies: 2 of the 3 patients had started their biotherapy less than a year before the onset of the urinary tract infection. Examination and clinical review should remain the primary elements in the diagnosis of a possible UTI and the therapeutic decision making.